VIDA
VIDA Diagnostics provides AI-powered quantitative imaging biomarker analysis and clinical trial imaging services to biopharma sponsors. Its cloud-based VIDA Intelligence Platform analyzes CT and MRI scans for respiratory, cardiovascular, and oncology trials, supported by a digital biobank of 500,000+ patients.
- Company typePrivate
- Founded2009
- HeadquartersCoralville, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What VIDA does
VIDA Diagnostics is a clinical imaging intelligence company founded in 2009 and headquartered in Coralville, Iowa, that builds AI-powered quantitative imaging biomarker solutions for respiratory, cardiovascular, and oncology clinical trials. Its core technology is the VIDA Intelligence Platform, a cloud-based system that ingests chest CT and, increasingly, MRI scans and applies proprietary deep-learning algorithms to extract up to 15,000 individual metrics per scan spanning 50+ biomarkers covering airway, parenchymal, vascular, and functional lung characteristics. The platform supports AI-powered digital biomarker analysis, expert reading services (eligibility reads, safety reads, adjudication), site onboarding and scanner certification, and sponsor trial orchestration, all backed by a Digital Biobank containing over 1 billion biological metrics, 500+ terabytes of multi-omic data, and records from more than 500,000 patients.
VIDA's product portfolio includes the VIDA Intelligence Platform (core cloud infrastructure), VIDA Discovery (clinical trial imaging services, formerly LungPrint Discovery), VIDA Insights (FDA-cleared point-of-care clinical software), the DTA Fibrosis Score for ILD, and a Cloud-Based Case Viewer. The company has built a dual distribution model combining direct enterprise sales to biopharma sponsors with channel partnerships through Nuance AI Marketplace (reaching 70% of US radiologists across 6,000+ facilities), TeraRecon EnvoyAI, Blackford, and IBM Watson Health. Revenue is generated primarily through enterprise service contracts for clinical trial imaging, recurring software licensing for VIDA Insights, and platform access fees, with regulatory clearances across the United States (FDA 510(k)), European Union (CE Mark), Canada, Australia (TGA), and Japan (PMDA) enabling global commercial reach.
VIDA has cumulatively raised approximately $33 million in venture funding, including a $13 million Series C in 2020 and a ~$10.8 million growth round in September 2023, with strategic investments from healthcare systems such as UnityPoint Health Ventures, OSF Ventures, and UW Health. The company has supported 60+ clinical trials across 30+ countries, operates a network of 1,500+ trial sites with 5,000+ users, and was recognized on the 2023 Inc. 5000 list for revenue growth and by Frost & Sullivan as 2020 Global Company of the Year in the radiology AI market for lung care. Recent strategic priorities include expansion into cardiovascular and oncology trial imaging, entry into functional MRI modalities through the Polarean partnership, and ecosystem-level integration of third-party algorithms from Riverain, Thirona, and other imaging AI specialists.
VIDA firmographics
Firmographics- Name
- VIDA
- Legal name
- VIDA Diagnostics, Inc.
- Website
- https://vidalung.ai
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- VIDA Diagnostics provides AI-powered quantitative imaging biomarker analysis and clinical trial imaging services to biopharma sponsors. Its cloud-based VIDA Intelligence Platform analyzes CT and MRI scans for respiratory, cardiovascular, and oncology trials, supported by a digital biobank of 500,000+ patients.
- Ownership category
- akta.pro rank
VIDA industry classification
Industry- Product category
- Clinical Imaging Intelligence
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
- akta.pro secondary industries
- Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Site Identification & Feasibility (HLAGACAB)
Keywords
Where VIDA is headquartered
LocationHeadquarters
- HQ city
- Coralville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
VIDA business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trial Imaging Services: VIDA provides platform-enabled clinical trial imaging services to biopharma sponsors, including site management, imaging data collection, AI-powered biomarker analysis, and expert reading services. Revenue derived from service contracts with pharmaceutical companies conducting imaging-based clinical trials.
- Software Licensing (VIDA Insights/LungPrint): Licensing of FDA-cleared, CE-marked software solutions for clinical use. Software available in US, EU, Canada, Australia, and Japan through distribution partnerships and direct sales.
- Platform Access and Integration: Cloud-based platform access provided to trial sites and sponsors, with integration into partner platforms (Nuance, TeraRecon, Blackford) expanding market reach and revenue opportunities.
Go-to-market motion2 records
Distribution channels6 records
Marketing channels7 records
VIDA product offering
Product offeringCore offering
VIDA Diagnostics provides AI-powered clinical trial imaging services and software to biopharma sponsors, enabling the collection, management, and analysis of quantitative imaging biomarkers throughout the drug development process. Its VIDA Intelligence Platform supports site management, trial orchestration, expert reading services, and AI-driven biomarker analysis across 1,500+ global sites, complemented by FDA-cleared clinical software (VIDA Insights/LungPrint) used by radiologists and pulmonologists at the point of care for early disease detection.
Product overview
VIDA is a clinical imaging intelligence company offering a platform-plus-modules architecture. The VIDA Intelligence Platform serves as the core cloud infrastructure enabling clinical trial imaging management and digital biobank capabilities. This platform is powered by two main product lines: VIDA Discovery (clinical trial services) and VIDA Insights (clinical care, formerly LungPrint). Supporting modules include the VIDA Intelligence Portal for trial site management, Cloud-Based Case Viewer for workflow efficiency, Digital Biobank for patient data repositories, DTA Fibrosis Score for ILD quantification, and comprehensive ILD imaging solutions. The portfolio also integrates best-of-breed partner algorithms including Thirona for thoracic imaging, Riverain for CT analysis, and Polarean for Xenon MRI functional assessment.
Differentiator
Problem solved
Functional benefit
Brands
- LungPrint: AI-powered imaging suite for pulmonary care, including LungPrint Discovery for automated radiological metrics and unique airway visualizations. LungPrint helps detect COPD and interstitial lung disease.
- VIDA Insights
- VIDA Intelligence Platform
- Digital Biobank
Products and services
- VIDA Intelligence Platform AI-powered cloud platform enabling biopharma sponsors to collect and leverage high-quality imaging data throughout drug development and clinical trial processes. Powers digital biobank, site operations, trial orchestration, and biomarker analysis across 1,500+ global sites.
- VIDA Insights (formerly LungPrint) FDA-cleared, CE-marked, Health Canada, TGA, and PMDA-certified AI-powered clinical solution for lung care teams to detect disease early, diagnose with confidence, and make personalized treatment decisions at the point of care.
- VIDA Discovery (formerly LungPrint Discovery)
Quantifiable outcome
- 700% growth in utilization of imaging biomarkers in clinical trials
- +4 more outcomes
Companies that use VIDA
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
VIDA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability6 records
Feature8 records
VIDA partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, major and strategic.
- PolareancoreVIDA partnered with Polarean to integrate Xenon MRI biomarker analysis into its clinical trial platform. VIDA provides centralized imaging operations and advanced biomarker analysis for Polarean's multi-center U.S. study in PH-ILD, enabling non-invasive, radiation-free imaging of the pulmonary capillary bed for cardiopulmonary drug development.
- Riverain TechnologiescoreStrategic partnership to integrate Riverain's ClearRead CT AI imaging analysis suite into VIDA's clinical trial platform. The collaboration aims to enhance biomarker data quality and operational efficiency for diseases like COPD, cardiovascular disease, and lung cancer, which collectively cause 40% of global deaths.
- ThironacoreVIDA partnered with Thirona to expand respiratory clinical trial imaging capabilities. Thirona provides advanced AI-powered analysis of thoracic imaging built on robust segmentation and precise quantification of bronchial, parenchymal, and vascular lung structures, available through VIDA's trial imaging solutions.
- OSIC (Open Source Imaging Consortium)coreVIDA's cloud platform powers OSIC Cloud, the world's largest and most diverse global repository for interstitial lung diseases. VIDA serves as both member and platform partner for OSIC, supporting its bold mission to advance ILD research and treatment.
- AWS (Amazon Web Services)coreVIDA leverages AWS cloud technologies for the VIDA Intelligence Platform, enabling scalable, secure cloud infrastructure for clinical trial imaging data management and analysis.
- National Jewish HealthcoreVIDA licensed the DTA (Data-Driven Texture Analysis) Fibrosis Score from National Jewish Health. The deep learning solution automatically quantifies lung fibrosis on HRCT scans and has been applied to tens of thousands of scans from diverse clinical trials, registries, and research cohorts.
- BlackfordmajorDistribution partner integrating LungPrint suite into radiology workflow for broader market access.
- IBM Watson HealthmajorDistribution partner for LungPrint suite integration into Watson Health ecosystem for enterprise healthcare customers.
- Nuance CommunicationsmajorVIDA joined Nuance AI Marketplace making LungPrint Discovery available to 70% of radiologists across 6,000+ healthcare facilities. Integrated with PowerScribe One radiology reporting platform.
- TeraReconmajorDistribution agreement with TeraRecon for LungPrint availability through AI Interoperability platform EnvoyAI, creating integrated physician experience.
- RAYUS RadiologystrategicVIDA and RAYUS Radiology partnered to empower imaging sites for decentralized clinical trials, enabling efficient trial participation.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
VIDA competitors and assessment
Company assessmentDirect peers
- Median Technologies: Median Technologies provides AI-driven imaging biomarkers and imaging trial management services to biopharma sponsors, with a particular focus on oncology. It is a directly comparable clinical trial imaging AI peer, operating in the same iCRO/imaging core lab category with similar SaaS-plus-services revenue model.
- Clario (formerly Bioclinica): Clario is a leading clinical trial endpoint and imaging core lab provider, offering centralized imaging services and software for clinical trials across multiple therapeutic areas. It directly competes with VIDA in respiratory/cardiac imaging core lab services and has substantially larger scale and sponsor footprint.
- Medidata (Dassault Systèmes): Medidata provides the Medidata Rave clinical trial platform including imaging management and eCOA capabilities used by sponsors globally. It is a peer in clinical trial informatics technology — the same category as VIDA's Intelligence Platform — and competes for sponsor technology budget.
- Riverain Technologies: Riverain Technologies provides AI-enabled chest CT analysis tools (ClearRead) for nodules, CAC, and lung tissue quantification — overlapping directly with VIDA's LungPrint. Notably, Riverain is now also a VIDA integration partner, reflecting both competitive and collaborative dynamics.
- Biomedical Systems (ERT/Clario): Biomedical Systems, now part of Clario, is a longstanding clinical trial imaging core lab with cardiac and respiratory imaging experience. It directly competes with VIDA for respiratory and cardiac imaging endpoint work in biopharma-sponsored trials.
Broad incumbents
- IQVIA: IQVIA is the world's largest CRO with embedded clinical trial imaging, real-world evidence, and data services. While broader and less specialized than VIDA, it competes for the same biopharma imaging endpoint budget and increasingly offers AI-driven imaging analytics as part of its portfolio.
- ICON plc: ICON plc is a global CRO with significant imaging and biomarker capabilities following its PRA Health Sciences and other acquisitions. It competes with VIDA for biopharma clinical trial imaging contracts but at a much broader scale across all therapeutic areas.
- Veeva Systems: Veeva provides cloud-based life sciences industry software, including Veeva Vault CTMS and eTMF for clinical trials. It is a broader incumbent in clinical trial technology that competes with VIDA's Intelligence Platform for sponsor platform budget.
Emerging players
- Aidoc: Aidoc is a leading clinical AI imaging platform deployed across hospital systems, with FDA-cleared algorithms spanning multiple body parts. It is an emerging competitor in radiology AI infrastructure and could expand into respiratory imaging where VIDA is specialized.
- Arterys (Tempus): Arterys, now part of Tempus, offers cloud-based AI medical imaging platforms with FDA-cleared algorithms for cardiac and lung MRI/CT. It is an emerging peer in clinical imaging AI infrastructure with comparable cloud-native architecture.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
VIDA social profiles
Digital presenceVIDA compliance and trust
Trust signalCompliance9 records
VIDA financial estimates
Financial estimateRevenue estimate
Valuation estimate
VIDA leadership team
Management profileNumber of profiles
Profiles8 records
VIDA funding detail
Funding detailFunding overview
Funding rounds8 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VIDA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VIDA
What does VIDA do?
VIDA Diagnostics provides AI-powered clinical trial imaging services and software to biopharma sponsors, enabling the collection, management, and analysis of quantitative imaging biomarkers throughout the drug development process. Its VIDA Intelligence Platform supports site management, trial orchestration, expert reading services, and AI-driven biomarker analysis across 1,500+ global sites, complemented by FDA-cleared clinical software (VIDA Insights/LungPrint) used by radiologists and pulmonologists at the point of care for early disease detection.
Is VIDA a public or private company?
VIDA is a private company. It is classified as venture growth investor backed and is currently operating.
When was VIDA founded?
VIDA was founded in 2009. It employs 101 to 250 people.
Where is VIDA based?
VIDA is headquartered in Coralville, United States, in the North America region.
How does VIDA make money?
Three revenue lines are on record. Clinical Trial Imaging Services are the primary driver. The others are software Licensing (VIDA Insights/LungPrint) and platform Access and Integration.
Who are VIDA's main competitors?
Direct peers on record are Median Technologies, Clario (formerly Bioclinica), Medidata (Dassault Systèmes), Riverain Technologies and Biomedical Systems (ERT/Clario). Broad incumbents are IQVIA, ICON plc and Veeva Systems. Emerging players are Aidoc and Arterys (Tempus).
Does VIDA have an API?
No public API is recorded for VIDA.
What industry is VIDA in?
VIDA's product category is Clinical Imaging Intelligence. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLAGACAG, Clinical Trial Monitoring Support (On-site/Remote). Its NAICS code is 5417 and its SIC code is 8731.